Fig. 7: Targeting MSX2 by morusinol prevents bone loss in OVX mice. | Nature Communications

Fig. 7: Targeting MSX2 by morusinol prevents bone loss in OVX mice.

From: Targeting Msx2 as a brake in the fusion fate of osteoclasts and an anabolic therapy in pre-clinical models of osteoporosis

Fig. 7: Targeting MSX2 by morusinol prevents bone loss in OVX mice.The alt text for this image may have been generated using AI.

a Schematic diagram for morusinol treatment in OVX mice, created by Biorender. b The 3D Micro-CT images of distal femurs from mice in Sham, OVX, and OVX+morusinol groups. c Bone morphology parameters of distal femurs (n = 10). d Representative TRAP staining images from Sham, OVX, and OVX + morusinol groups. Scale bar, 100 μm. e Quantification of Mu.Oc.N/BS and Mo.Oc.N/BS (n = 5). f Serum CTX-1 levels were detected by ELISA (n = 5). g Immunofluorescence staining of PU.1 and CTSK in distal femurs from OVX and OVX+morusinol groups. Scale bar, 50 μm. h Quantification of PU.1+ CTSK+ cell number/ BS (n = 5). i Calcein labeling images from OVX and OVX+morusinol groups. Scale bar, 25 μm. j Quantification of MAR and BFR/BS (n = 5). k Immunofluorescence staining of OCN in distal femurs from OVX and OVX + morusinol groups. Scale bar, 50 μm. l N.OCN+ cells/BS was measured (n = 5). m Representative images of immunofluorescence staining of EMCNhi CD31hi vessels. Scale bar, 50 μm. n Quantification of CD31hi EMCNhi.Ar (n = 5). Data are presented as mean ± SD, and p-values were calculated by unpaired, two-tail student’s t-test (h, j, and l) and one-way ANOVA with Tukey’s multiple comparisons (c, e, f, and n).

Back to article page